Transplantation & Cellular Therapy
The latest news, research, and perspectives in transplantation and cellular therapy. Hematopoietic cell transplantation involves replacing unhealthy bone marrow with healthy stem cells in patients with hematologic disorders. In the growing field of non-transplant cellular therapies, including chimeric antigen receptor T-cell therapies, patient- or donor-derived cells are being explored for the treatment and potential cure of blood cancers.
Advertisement
Overall survival was also greater in the study comparing the treatments in ALL, AML, MDS, and mixed-phenotype acute leukemia.
Azercabtagene zapreleucel applies a novel approach of combining lymphodepletion chemotherapy with interleukin-2.
The FDA approvals of CAR T-cell therapies have changed the treatment landscape for several hematologic malignancies.
The experts focused on cilta-cel when comparing the three FDA-approved treatments' efficacies, toxicities, and availability.
New data on immune thrombocytopenia were most prominent but Meeting coverage ranged over several forms of the disease.
Melody Smith, MD, MS, shares data on burnout in hematologist oncologists, why it occurs, and how to prevent it.
Advertisement
Cema-cel is feasible and can induce durable responses in patients with LBCL, achieving an ORR of 58% and a CR rate of 42%.
A panel moderated by Neil Love, MD, explored clinical data to assess these treatment approaches for the various types of NHL.
Real-world data shows evolving treatment strategies and clinical decision-making.
The phase 2 prospective trial with these results also evaluated overall survival, nonrelapse mortality, and relapse rates.
Adding ruxolitinib before, during, and after HSCT to standard GVHD prophylaxis reduced the incidence of GVHD.
Scientific evidence indicates that CAR-T can be safely administered on an outpatient basis at specialized medical centers.
Findings from a subgroup analysis of ZUMA-7 support early referral to axi-cel therapy.
In a prospective study patients with Fanconi anemia were matched to healthy controls and underwent carotid artery ultrasound.
Patient-reported response is associated with overall response, total symptom score response, and failure-free survival.
In the TRANSCEND FL trial liso-cel has met primary and secondary endpoints for both MZL and FL with manageable safety.
The positive opinion is based on results from the phase II TRANSCEND FL study, in which liso-cel showed an ORR of 97.1%.
This new indication for the injection alkylating agent pertains to adult or pediatric patients aged one year and older.
The therapies are under development for EBV-positive PTLD, non-Hodgkin lymphoma, and systemic lupus erythematosus.
The CRL is related to observations of a third-party manufacturing facility as part of a standard prelicense inspection.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.